Showing 3471-3480 of 5621 results for "".
- Luxa Biotechnology Presents Data from First-in-Human Retinal Pigment Epithelium Cell Therapy for Dry AMDhttps://modernod.com/news/luxa-biotechnology-presents-data-from-first-in-human-retinal-pigment-epithelium-cell-therapy-for-dry-amd/2482693/Luxa Biotechnology announced clinical data from its phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE) cell therapy for patients with dry age-related macular degeneration (AMD). The data were presented at the 77th Annual Wills Eye Conference in Phila
- Lumata Health Secures $23 Million Series B Fundinghttps://modernod.com/news/lumata-health-secures-23-million-series-b-funding/2482691/Lumata Health announced that it has raised $23 million in Series B funding, bringing its total raised since inception to $36 million. Lumata said the investment will enable the company to meet growing demand and further enhance the data-driven technology powering its patient adherence s
- Optos Unveils MonacoPro Ultra-Widefield and OCT Retinal Imaging Technologyhttps://modernod.com/news/optos-unveils-monacopro-ultra-widefield-and-oct-retinal-imaging-technology/2482688/Optos announced the launch of MonacoPro, the next generation ultra-widefield (UWF) SLO and spectral domain retinal imaging solution. Building on the legacy of Monaco, Optos said MonacoPro introduces features designed to elevate diagnostic precision and streamline workflow for eye care profes
- Haag-Streit Launches METIS 900 Ophthalmic Surgical Microscopehttps://modernod.com/news/haag-streit-launches-metis-900-new-ophthalmic-surgical-microscope/2482687/Haag-Streit announced the launch of the METIS 900 ophthalmic microscope system. According to Haag-Streit, the METIS 900 was designed to maximize clarity and precision of visualization during surgeries, as well as the surgeon’s comfort. Programmable hand and/or foot switches
- Adverum Initiates ARTEMIS Phase 3 Study to Evaluate Ixo-vec for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-initiates-artemis-phase-3-study-to-evaluate-ixo-vec-for-wet-amd/2482686/Adverum Biotechnologies announced the initiation of ARTEMIS phase 3 study to evaluate Ixo-vec gene therapy (ixoberogene soroparvovec) as a one-time intravitreal (IVT) injection for neovascular (wet) age-related macular degeneration (AMD). Wet AMD is a leading cause of blindness in the e
- Opthea Publishes Phase 2b Trial Data for Wet AMDhttps://modernod.com/news/opthea-publishes-promising-phase-2b-trial-data-for-wet-amd/2482685/Opthea announced new data from the phase 2b clinical trial using sozinibercept to treat wet age-related macular degeneration (AMD). The results were published in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. Opthea’s complete phase 3 wet AMD
- Altris AI Launches Advanced Optic Disc Analysis for Glaucomahttps://modernod.com/news/altris-ai-launches-advanced-optic-disc-analysis-for-glaucoma-complementing-gcc-asymmetry-analysis/2482683/Altris AI, a provider of AI OCT scan analysis for the detection of a range of retina pathologies and biomarkers, announced the launch of an advanced glaucoma 'Optic Disc Analysis' module. To address need to improve timely and accurate gl
- Mount Sinai Team Identifies Underlying Mechanisms of Age-Related Meibomian Gland Dysfunction, Possible Treatment Options for Dry Eye Diseasehttps://modernod.com/news/mount-sinai-team-identifies-underlying-mechanisms-of-age-related-meibomian-gland-dysfunction-possible-treatment-for-dry-eye-disease/2482679/New research from Mount Sinai identifies an underlying molecular mechanism of age-related degeneration in the meibomian glands essential to normal eye function. Now, this may lead to new therapeutic approaches for common conditions in older adults such as evaporated dry eye disease.
- World’s First AI-Powered Cardiovascular Retinal Screening to be Launched in the UKhttps://modernod.com/news/worlds-first-ai-powered-cardiovascular-retinal-screening-to-be-launched-in-the-uk/2482674/Heart Eye has unveiled AI-powered cardiovascular screening technology using retinal imaging in the UK. The company says the technology delivers patients’ cardiovascular disease risk results in just 3 minutes. The technology, called '
- Seonix Bio Launches SightScore, the First Clinical Polygenic Risk Score Test for Glaucoma in the UShttps://modernod.com/news/seonix-bio-launches-sightscore-the-first-clinical-polygenic-risk-score-test-for-glaucoma-in-the-us/2482672/Seonix Bio announced the US launch of SightScore, which the company descibes as the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma. Already available in Australia and New Zealand, SightScore utilizes